Added to YB: 2025-10-08
Pitch date: 2025-10-05
AZN [neutral]
AstraZeneca PLC
+5.73%
current return
Author Info
Disruptive Analytics has 30+ years of experience as a retail investor and is now fully engaged in managing their own money. Sign up for the newsletter.
Company Info
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Market Cap
GBP 290.3B
Pitch Price
GBP 127.16
Price Target
N/A
Dividend
1.71%
EV/EBITDA
15.18
P/E
31.11
EV/Sales
5.42
Sector
Pharmaceuticals
Category
growth
Targeted Chemotherapy - AstraZeneca PLC
AZN (overview): Quality oncology leader with Enhertu ADC 'smart bomb' generating $2.5B revenue 2024, expanding approvals across breast/lung cancers. Strong portfolio (Tagrisso, Imfinzi, Calquence, Truqap) positioned for cash flow growth next decade. Historically overvalued but ~10% 1yr return suggests potential entry point despite premium pricing.
Read full article (1 min)